Bioactive Products
| A unique collection of 674 anticancer natural compounds for high throughput screening (HTS) and New anticancer drug research | ||
| Catalog No: | B91 | Anticancer Compound Library Screening Details |
| Size: | 1mg/well * 674 Compounds 2mg/well * 674 Compounds | |
| Cat. No. | Information |
| CFN97048 | Acteoside Acteoside is a lipase inhibitor, has neuroprotective, anti-obesity,anti-inflammatory, antioxidant, anticancer, cytotoxic,antihypertensive, analgesic, and antimetastatic activities. Acteoside can promote nerve growth factor and tropomycin receptor kinase A expression, inhibit arachidonic acid release and prostaglandin E2 production induced by 0.5 microM melittin. Acteoside can protect the cells from X‑ray induced damage through enhancing the scavenging activity of ROS, decreasing the Bax/Bcl-2 ratio and downregulating the activity of procaspase-3, as well as modulating the mitogen‑activated protein kinase signaling pathways. |
| CFN97050 | alpha-Mangostin Alpha-Mangostin has neuroprotective, anti-cancer, antifungal, neuroprotective, renoprotective, antioxidant and anti-inflammatory activities. Alpha-Mangostin exhibits peripheral and central antinociception through modulation of opioid and vanilloid receptors, the glutamatergic system, and the larginine/NO/cGMP/PKC/K(+)-ATP pathways; it suppresses phorbol 12-myristate 13-acetate-induced MMP-2/MMP-9 expressions via alphavbeta3 integrin/FAK/ERK and NF-kappaB signaling pathway in human lung adenocarcinoma A549 cells. Alpha-Mangostin is also a novel competitive histamine H1 receptor antagonist in smooth muscle cells. |
| CFN90123 | Gomisin G Gomisin G is a drug candidate for treatment of cardiovascular disease, and it is a good substrate of CYP2C9, and can be easily affected by the inhibitors of CYP2C9. Gomisin G exhibits anti-tumor activities, it exhibits potent anti-HIV activity with EC50 and therapeutic index (TI) values of 0.006 microgram/mL and 300, respectively. |
| CFN90124 | Gomisin J Gomisin J is a good substrate of cytochrome P450 3A4(CYP3A4), it has vasodilatory, anti-inflammatory, anti-diabetes, anti-oxidant, and anti-cancer effects, it also has preventive effects on angiotensin II-induced hypertension via an increased nitric oxide bioavailability. Gomisin J has potential benefits in treating nonalcoholic fatty liver disease, it can suppress lipid accumulation by regulating the expression of lipogenic and lipolytic enzymes and inflammatory molecule. Halogenated gomisin J is a potent inhibitor of the cytopathic effects of human immunodeficiency virus type 1 (HIV-1) on MT-4 human T cells (50% effective dose, 0.1 to 0.5 microM). |
| CFN90125 | Gomisin N Gomisin N has anti-oxdiant, anti-inflammatory, anti-cancer and anti-hepatitis activities; it produces beneficial sedative and hypnotic bioactivity, which may be mediated by the modification of the serotonergic and GABAergic system. Gomisin N can enhance TNF-α-induced apoptosis by suppressing of NF-κB and EGFR signaling pathways, and potentiate TRAIL-induced apoptosis through ROS-mediated up-regulation of death receptors 4 and 5. |
